Regenxbio announces fda clearance of ind for phase ii trial of rgx-314

Regenxbio announces fda clearance of ind for phase ii trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery.regenxbio inc - regenxbio plans to begin dosing patients in a phase ii trial, altitude, in second half of 2020.regenxbio inc - long-term treatment with anti-vegf injections has been shown to reduce severity of dr and prevent vision threatening complications.regenxbio inc - expects to report interim data from phase 2 trial in 2021.
RGNX Ratings Summary
RGNX Quant Ranking